Encompass Health (NYSE:EHC) Price Target Raised to $118.00

Encompass Health (NYSE:EHC) had its target price hoisted by Barclays from $116.00 to $118.00 in a research report report published on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages have also issued reports on EHC. Truist Financial reissued a “buy” rating and issued a $116.00 price target (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Royal Bank of Canada boosted their target price on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. KeyCorp raised their price target on Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Finally, William Blair reiterated an “outperform” rating on shares of Encompass Health in a research report on Friday. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $107.33.

Encompass Health Stock Up 1.3 %

NYSE:EHC opened at $99.86 on Friday. The stock’s fifty day simple moving average is $96.28 and its 200-day simple moving average is $95.30. The firm has a market capitalization of $10.06 billion, a P/E ratio of 22.39, a P/E/G ratio of 1.18 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. Encompass Health has a 12-month low of $72.37 and a 12-month high of $104.55.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. Equities research analysts expect that Encompass Health will post 4.76 earnings per share for the current year.

Hedge Funds Weigh In On Encompass Health

A number of large investors have recently bought and sold shares of the company. State Street Corp lifted its position in shares of Encompass Health by 0.7% in the third quarter. State Street Corp now owns 3,025,769 shares of the company’s stock worth $292,410,000 after purchasing an additional 21,329 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Encompass Health by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock valued at $161,781,000 after buying an additional 20,547 shares in the last quarter. Copeland Capital Management LLC grew its position in shares of Encompass Health by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company’s stock valued at $119,418,000 after acquiring an additional 8,548 shares during the period. Point72 Asset Management L.P. increased its stake in shares of Encompass Health by 2,458.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock worth $83,990,000 after purchasing an additional 835,135 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Encompass Health in the 4th quarter valued at about $77,944,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.